<?xml version='1.0' encoding='utf-8'?>
<document id="31060033"><sentence text="Studies of pharmacokinetics in beagle dogs and drug-drug interaction potential of a novel selective ZAK inhibitor 3h for hypertrophic cardiomyopathy treatment." /><sentence text="Overexpression of leucine-zipper and sterile-α motif kinase (ZAK) in heart has been closely associated with the development of hypertrophic cardiomyopathy (HCM)"><entity charOffset="18-25" id="DDI-PubMed.31060033.s2.e0" text="leucine" /></sentence><sentence text=" N-(3-(1H-pyrazolo[3,4-b]pyridin-5-yl)ethynyl) benzene-sulfonamides, novel highly selective ZAK inhibitors, had exhibited reasonable orally therapeutic effects on HCM in spontaneous hypertensive rat models"><entity charOffset="1-67" id="DDI-PubMed.31060033.s3.e0" text="N-(3-(1H-pyrazolo[3,4-b]pyridin-5-yl)ethynyl) benzene-sulfonamides" /></sentence><sentence text=" In the present study, a rapid and sensitive HPLC-MS/MS method for determining ZAK inhibitor 3h in beagle dog plasma was developed and validated" /><sentence text=" Meanwhile, the pharmacokinetics in beagle dog and drug-drug interaction potential of 3h had been conducted" /><sentence text=" The pharmacokinetic results showed that the absolute oral bioavailability for 3h in beagle dogs was determined to be 61" /><sentence text="9%, which was significantly higher than that in the previous determination in Spragur-Dawley rats (F = 20%)" /><sentence text=" The Cytochrome P450 enzymes and P-glycoprotein mediated drug-drug interactions by 3h were also investigated using dog and human liver microsomes and Caco-2 cells" /><sentence text=" The results demonstrated that only CYP2C9 was obviously inhibited (IC50 = 1" /><sentence text="66 μM)" /><sentence text=" Besides, 3h could significantly decrease digoxin efflux ratio in Caco-2 experiments in a dose-dependent manner (IC50 = 13" /><sentence text="3 μM)" /><sentence text=" Considering 3h strongly suppressed the ZAK kinase activity with an IC50 of 3" /><sentence text="3 nM, there are significantly differences between this IC50 value for ZAK inhibition and the present determinations of IC50 values" /><sentence text=" In general, the clinical drug-drug interaction potential for 3h could be well monitored during the treatment of HCM" /><sentence text="" /></document>